Synthesis and cytostatic activity of substituted 6-phenylpurine bases and nucleosides: Application of the Suzuki-Miyaura cross-coupling reactions of 6-chloropurine derivatives with phenylboronic acids

Journal of Medicinal Chemistry

Volumn 43, Issue 9, 2000, Pages 1817-1825

  Hocek, Michal ^a   Holý, Antonín ^a   Votruba, Ivan ^a   Dvořáková, Hana ^b  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; NUCLEOSIDE DERIVATIVE; PURINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOSTASIS; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL SURVIVAL; HELA CELLS; HUMANS; LEUKEMIA L1210; LEUKEMIA, T-CELL, ACUTE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PURINES; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034069172     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm991167+     Document Type: Article

References (75)

1. (a) Robins, R. K.; Revankar, G. R. Purine analogues and related nucleosides and nucleotides as antitumor agents. Med. Res. Rev. 1985, 5, 273-296.
2. (b) Plunkett, W.; Saunders, P. P. Metabolism and action of purine nucleoside analogues. Pharmacol. Ther. 1991, 49, 239-268.
3. (c) Cheson, B. D. Perspectives on purine analogues. Hematol. Cell Ther. 1996, 38 (Suppl. 2), S109-S116.
4. (d) Bergmann, L. Present status of purine analogues in the therapy of chronic lymphocytic leukemias. Leukemia 1997, 11 (Suppl. 2), S29-S34.
5. (a) Veselý, J.; Havlíček, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.; Detivaud, L.; Leclerc, S. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224, 771-786.
6. (b) Havlíček, L.; Hanus, J.; Veselý, J.; Leclerc, S.; Meijer, L.; Shaw, G.; Strnad, M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 1997, 40, 408-412.
7. (c) Legraverend, M.; Ludwig, O.; Bisagni, E.; Leclerc, S.; Meijer, L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. 1998, 8, 793-798.
8. (d) Legraverend, M.; Ludwig, O.; Bisagni, E.; Leclerc, S.; Meijer, L.; Giocanti, N.; Sadri, R.; Favaudon, V. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. 1999, 7, 1281-1293.
9. (e) N.Oh, C. H.; Lee, S. C.; Lee, K. S.; Woo, E. R.; Hong, C. Y.; Yang, B. S.; Baek, D. J.; Cho, J. H. Synthesis and biological activities of C-2, N-9 substituted 6-benzylamino-purine derivatives as cyclin-dependent kinase inhibitors. Arch. Pharm. (Weinheim) 1999, 332, 187-190.
10. Revankar, G. R.; Robins, R. K. Heterocyclic Analogues of Purine Nucleosides and Nucleotides. In Chemistry of Nucleosides and Nucleotides; Townsend, L. B., Ed.; Plenum Press: New York/ London, 1988; Vol. 2, pp 200-246.
11. (a) Cristalli, G.; Franchetti, P.; Grifantini, M.; Vittori, S.; Bordoni, T.; Geroni, C. Improved synthesis and antitumor activity of 1-deazaadenosine. J. Med. Chem. 1987, 30, 1686-1688.
12. (b) Cristalli, G.; Vittori, S.; Eleuteri, A.; Grifantini, M.; Volpini, R.; Lupidi, G.; Capolongo, L.; Pesenti, E. Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity. J. Med. Chem. 1991, 34, 2226-2230.
13. Franchetti, P.; Cappellacci, L.; Grifantini, M.; Lupidi, G.; Nocentini, G.; Barzi, A. 8-Aza Analogues of Deaza Purine Nucleosides - Synthesis and Biological Evaluation of 8-Aza-1-deazaadenosine and 2′-Deoxy-8-aza-1-deazaadenosine. Nucleosides Nucleotides 1992, 11, 1059-1076.
14. (a) Leopold, W. R.; Fry, D. W.; Boritzki, T. J.; Besserer, J. A.; Pattison, I. C.; Jackson, R. C. Deazaguanine mesylate: a new antipurine antimetabolite. Invest. New Drugs 1985, 3, 223-231.
15. (a) Page, T.; Jacobsen, S. J.; Smejkal, R. M.; Scheele, J.; Nyhan, W. L.; Mangum, J. H.; Robins, R. K. Studies on the mechanism of cytotoxicity of 3-deazaguanosine in human cancer cells. Cancer Chemother. Pharmacol. 1985, 15, 59-62.
16. (b) Jacobsen, S. J.; Page, T.; Diala, E. S.; Nyhan, W. L.; Robins, R. K.; Mangum, J. H. Synergistic activity of purine metabolism inhibitors in cultured human tumor cells. Cancer Lett. 1987, 35, 97-104.
17. Pudlo, J. S.; Nassiri, M. R.; Kern, E. R.; Wotring, L. L.; Drach, J. C.; Townsend, L. B. Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. J. Med. Chem. 1990, 33, 1984-1992.
18. Elion, G. B.; Hitchings, G. H. Metabolic basis for the actions of analogues of purines and pyrimidines. Adv. Chemother. 1965, 2, 91-177.
19. For review: Benezra, S. A.; Foss P. R. B. In Analytical Profiles of Drug Substances;Florey, K., Ed.; Academic Press: New York, 1978; pp 343-357.
20. (a) Avery, T. L.; Finch, R. A.; Vasquez, K. M.; Radparvar, S.; Hanna, N. B.; Revankar, G. R.; Robins, R. K. Chemotherapeutic characterization in mice of 2-amino-9-beta-D-ribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties. Cancer Res. 1990, 50, 2625-2630.
21. (b) Revankar, G. R.; Hanna, N. B.; Imamura, N.; Lewis, A. F.; Larson, S. B.; Finch, R. A.; Avery, T. L.; Robins, R. K. Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides. J. Med. Chem. 1990, 33, 121-128.
22. (c) Hanna, N. B.; Bhattacharya, B. K.; Robins, R. K.; Avery, T. L.; Revankar, G. R. Sulfinosine Congeners - Synthesis and Antitumor Activity in Mice of Certain N9-Alkylpurines and Purine Ribonucleosides. J. Med. Chem. 1994, 37, 177-183.
23. Williams, B. A.; Blay, J.; Hoskin, D. W. 2-chloroadenosine stimulates granule exocytosis from mouse natural killer cells: Evidence for signal transduction through a novel extracellular receptor. Exp. Cell Res. 1997, 233, 187-197.
24. (a) Wataya, Y.; Hirota, Y.; Hiramoto-Yoshioka, A.; Tanaka, S.; Otani, T.; Minowada, J.; Matsuda, A.; Ueda, T. The mechanism of 2-chlorodeoxyadenosine-induced cell death. Adv. Exp. Med. Biol. 1989, 253B, 227-234.
25. (b) Carson, D. A.; Wasson, D. B.; Taetle, R.; Yu, A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983, 62, 737-743.
26. (c) Carson, D. A.; Wasson, D. B.; Beutler, E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 2232-2236.
27. (a) Reiter, Z.; Tomson, S.; Ozes, O. N.; Taylor, M. W. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation. Blood 1993, 81, 1699-1708.
28. (b) Saven, A.; Carrera, C. J.; Carson, D. A.; Beutler, E.; Piro, L. D. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992, 80, 587-592.
29. (c) Arner, E. S. J. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leuk. Lymphoma 1996, 21, 225-231.
30. (a) Keating, M. J.; Kantarian, H.; Talpaz, M. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989, 74, 19-25.
31. (b) Pawelski, S. Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders. Acta Haematol. Pol. 1995, 26, 263-268.
32. (c) Fludarabine phosphate: an effective therapy for lymphoid malignancies. Semin. Oncol. 1990, 17, 1-78.
33. Matsuda, A.; Shinozaki, M.; Yamaguchi, T.; Homma, H.; Nomoto, R.; Miyasaka, T.; Watanabe, Y.; Abiru, T. Nucleosides and Nucleotides. 103. 2-Alkynyladenosines - A Novel Class of Selective Adenosine-A2 Receptor Agonists with Potent Antihypertensive Effects. J. Med. Chem. 1992, 35, 241-252.
34. Lambe, C. U.; Averett, D. R.; Paff, M. T.; Reardon, J. E.; Wilson, J. G.; Krenitsky, T. A. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995, 55, 3352-3356.
35. (a) Gibboney, D. S.; French, B. T.; Patrick, D. E.; Trewyn, R. W. 6-ethylmercaptopurine-mediated growth inhibition of HL-60 cells in vitro irrespective of purine salvage. Cancer Chemother. Pharmacol. 1989, 25, 189-194.
36. (b) Akiyama, S. I.; Kuwano, M.; Komiyama, S.; Saneyoshi, M. Antitumor effect of a combination of 6-methylthioinosine and amphotericin B on mouse leukemia L1210. Cancer Lett. 1980, 9, 305-311.
37. (a) McGarrity, G. J.; Carson, D. A. Adenosine phosphorylase-mediated nucleoside toxicity. Application towards the detection of mycoplasmal infection in mammalian cell cultures. Exp. Cell Res. 1982, 139, 199-205.
38. (b) Whitaker, A. M.; Windsor, G. D.; Burnett, C. M.; Taylor, C. H. A rapid and sensitive method for the detection of mycoplasmas in infected cell cultures using 6-methylpurine deoxyriboside. Dev. Biol. Stand. 1987, 66, 503-509.
39. (c) Ishiguro, K.; Taira, S.; Sasaki, T.; Nariuchi, H. Depletion of mycoplasma from infected cell lines by limiting dilution in 6-methylpurine deoxyriboside. J. Immunol. Methods 1988, 108, 39-43.
40. (a) Parker, W. B.; King, S. A.; Allan, P. W.; Bennett, L. L., Jr.; Secrist, J. A.; Montgomery, J. A.; Gilbert, K. S.; Waud, W. R.; Wells, A. H.; Gillespie, G. Y.; Sorscher, E. J. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther. 1997, 8, 1637-1644.
41. (b) Parker, W. B.; Allan, P. W.; Shaddix, S. C.; Rose, L. M.; Speegle, H. F.; Gillespie, G. Y.; Bennett, L. L., Jr. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 1998, 55, 1673-1681.
42. Brathe, A.; Gundersen, L. L.; Rise, E.; Eriksen, A. B.; Vollsnes, A. V.; Wang, L. N. Synthesis of 6-alkenyl- and 6-alkynylpurines with cytokinin activity. Tetrahedron 1999, 55, 211-228.
43. (a) Kobayashi, Y.; Yamamoto, K.; Asai, T.; Nakano, M.; Kumadaki, I. Studies on Organic Fluorine Compounds. Part 35. Trifluoromethylation of Pyrimidine- and Purine-nucleosides with Trifluoromethyl-Copper Complex. J. Chem. Soc., Perkin Trans. 1 1980, 2755-2761.
44. (b) Hocková, D.; Hocek, M.; Dvořáková, H.; Votruba, I. Synthesis and Cytostatic Activity of Nucleosides and Acyclic Nucleoside Analogues Derived form 6-(Trifluoromethyl)-purines. Tetrahedron 1999, 55, 11109-11118.
45. Cocuzza, A. J.; Chidester, D. R.; Culp, S.; Fitzgerald, L.; Gilligan, P. Use of Suzuki Reaction for the Synthesis of Aryl-substituted Heterocycles as Corticotropin-Releasing Hormone (CHR) Antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 1063-1066.
46. (a) Moran, S.; Ren, R. X. F.; Rumney, S., IV; Kool, E. T. Difluorotoluene, A Nonpolar Isostere for Thymine, Codes Specifically and Efficiently for Adenine in DNA Replication. J. Am. Chem. Soc. 1997, 119, 2056-2057.
47. (b) Liu, D.; Moran, S.; Kool, E. T. Bi-stranded, multisite replication of a base pair between difluorotoluene and adenine: confirmation by 'inverse' sequencing. Chem. Biol. 1997, 4, 919-926
48. (c) Guckian, K. M.; Krugh, T. R.; Kool, E. T. Solution structure of a DNA duplex containing a replicable difluorotoluene-adenine pair. Nat. Struct. Biol. 1998, 5, 954-959.
49. (a) Bergstrom, D. E.; Reddy, P. A. Synthesis of 6-Alkyl and 6-Aryl Substituted 9-β-D-ribofuranosyl Purines via the Nickel Catalyzed Coupling of Grignard Reagents to 2′,3′,5′-Tris-O-(tert-butyldimethylsilyl)-9-β-D- ribofuranosyl-6-chloropurine. Tetrahedron Lett. 1982, 23, 4191-4194.
50. (b) Estep, K. G.; Josef, K. A.; Bacon, E. R.; Carabates, P. M.; Rumney, S., IV; Pilling, G. M.; Krafte, D. S.; Volberg, W. A.; Dillon, K.; Dugrenier, N.; Briggs, G. M.; Canniff, P. C.; Gorczyca, W. P.; Stankus, G. P.; Ezrin, A. M. Synthesis and Structure-Activity Relationship of 6-Heterocyclic-Substituted Purines as Inactivation Modifiers of Cardiac Sodium Channels. J. Med. Chem. 1995, 38, 2582-2595.
51. (a) Gundersen, L. L. 6-Chloropurines and Organostannanes in Paladium Catalyzed Cross Coupling Reactions. Tetrahedron Lett. 1994, 35, 3155-3158.
52. (b) Gundersen, L. L.; Bakkestuen, A. K.; Aasen, A. J.; Øveras, H.; Rise, F. 6-Halopurines in Palladium-Catalyzed Coupling with Organotin and Organozinc Reagents. Tetrahedron 1994, 50, 9743-9756.
53. (c) Hocek, M.; Masojídková, M.; Holý, A. Synthesis of Acyclic Nucleotide Analogues Derived from N-substituted 6-(1-Aminomethyl)purines via 6-Acetylpurine Derivatives. Tetrahedron 1997, 53, 2291-2302.
54. (d) Hocek, M.; Masojídková, M.; Holý, A. Synthesis of Acyclic Nucleotide Analogues Derived from 6-Hetarylpurines via Cross-Coupling Reactions of 9-[2-(Diethoxyphosphonylmethoxy)ethyl]-6-iodopurine with Hetaryl Organometallic Reagents. Collect. Czech. Chem. Commun. 1997, 62, 136-146.
55. (e) Van Aerschot, A. A.; Mamos, P.; Weyns, N. J.; Ikeda, S.; De Clercq, E.; Herdewijn, P. Antiviral Activity of C-Alkylated Purine Nucleosides Obtained by Cross-Coupling with Tetraalkyltin Reagents. J. Med. Chem. 1995, 36, 2938-2942.
56. Hirota, K.; Kitade, Y.; Kanbe, Y.; Maki, Y. Convenient Method for the Synthesis of C-Alkylated Purine Nucleosides: Palladium-Catalyzed Cross-Coupling Reaction of Halopurine Nucleosides with Trialkylaluminums. J. Org. Chem. 1992, 57, 5268-5270.
57. (a) McKenzie, T. C.; Glass, D. The Reaction of 6-Halopurines with Phenyl Metal Complexes. J. Heterocycl. Chem. 1987, 24, 1551-1553.
58. (b) Dvořáková, H.; Dvořák, D.; Holý, A. Coupling of 6-Chloropurines with Organocuprates Derived from Grignard Reagents: A Convenient Route to sec- and tert- 6-Alkylpurines. Tetrahedron Lett. 1996, 37, 1285-1288.
59. (c) Dvořáková, H.; Dvořák, D.; Holý, A. Synthesis of Acyclic Nucleotide Analogues Derived from 6-(sec- or tert-Alkyl)purines via Coupling of 6-Chloropurine Derivatives with Organocuprates. Collect. Czech. Chem. Commun. 1998, 63, 2065-2074.
60. (d) Hocek, M.; Holý, A. Perfluoroalkylation of 6-Iodopurines by Trimethyl(perfluoroalkyl)silanes. Synthesis of 6-(Perfluoroalkyl)purine Bases, Nucleosides and Acyclic Nucleotide Analogues. Collect. Czech. Chem. Commun. 1999, 64, 229-241.
61. (a) Stevenson, T. M.; Prasad, A. S. B.; Citineni, J. B.; Knochel, P. Preparation of Zinc Organometallics Derived from Nucleosides and Nucleic Acid Bases and Pd(0) Catalyzed Coupling with Aryl Iodides. Tetrahedron Lett. 1996, 37, 8375-8378.
62. (b) Prasad, A. S. B.; Stevenson, T. M.; Citineni, J. B.; Nyzam, V.; Knochel, P. Preparation and Reactions of New Zincated Nitrogen-Containing Heterocycles. Tetrahedron 1997, 53, 7237-7254.
63. (a) Nair, V.; Richardson, S. G.; Coffman, R. E. Arylation and Heteroarylation of Photochemically Generated Purinyl Radicals. J. Org. Chem. 1982, 47, 4520-4524.
64. (b) McKenzie, T. C.; Epstein, J. W. Coupling of Diazopurines, a Curious Steric Effect in a Free Radical Reaction. J. Org. Chem. 1982, 47, 4881-4884.
65. (c) Nair, V.; Young, D. A. Synthetic Transformations of Transient Purinyl Radicals: Formation of Mono- and Diarylated and Heteroarylated Nucleosides. J. Org. Chem. 1984, 49, 4340-4344.
66. Havelková, M.; Hocek, M.; Česnek, M.; Dvořák, D. The Suzuki-Miyaura Cross-Coupling Reactions of 6-Halopurines with Boronic Acids Leading to 6-Aryl- and 6-Alkenylpurines. Synlett 1999, 1145-1147
67. Robins, R. K.; Godefroi, E. F.; Taylor, E. C.; Lewis, L. R.; Jackson, A. Purine Nucleosides. I. The Synthesis of Certain 6-Substituted-9-(tetrahydro-2-pyranyl)-purines as Model of Purine Deoxynucleotides. J. Am. Chem. Soc. 1961, 83, 2574-2579.
68. Hocek, M.; Holý, A. A Facile Synthesis of 6-Cyanopurine Bases. Collect. Czech. Chem. Commun. 1995, 60, 1386-1389.
69. Buck, I. M.; Reese, C. B. An Unambiguous Synthesis of Adenylsuccinic Acid and its Constituent Nucleoside. J. Chem. Soc., Perkin Trans. 1 1990, 2937-2942.
70. Robins, M. J.; Uznanski, B. Nucleic Acids Related Compounds. 33. Conversions of Adenosine and Guanosine to 2,6-Dichloro, 2-Amino-6-chloro, and Derived Purine Nucleosides. Can. J. Chem. 1981, 59, 2601-2607.
71. Sugimura, H.; Takei, H. Synthesis of 6-Alkylpurine Derivatives by Nickel-Complex-Catalyzed Coupling Reaction of 6-(Methylthio)purine derivatives with Grignard Reagents. Bull. Chem. Soc. Jpn. 1985, 58, 664-666.
72. NANRORC Mechanism in the Amination of 2-Substituted Purines with Potassium Amide in Liquid Ammonia. J. Org. Chem. 1980, 45, 2942-2945.
73. Veselý, J. Synergistic effect of cis-dichlorodiammineplatinum and 5-aza-2′-deoxycytidine on mouse leukemic cells in vivo and in vitro. Int. J. Cancer 1982, 29, 81-85.
74. Lillie, R. D. H. J. Conn's Biological Stains, 9th ed.; Williams & Wilkins: Baltimore, 1977.
75. Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47, 936-942.